Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Kulke

Showing results (81-90 of 182) with videos related to

Pageof 19
Sort By:
Cancer|June 5, 2013
A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumorJennifer A Chan, Lawrence Blaszkowsky, Keith Stuart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2005
Assessment of a dietary questionnaire in cancer patients receiving cytotoxic chemotherapyJeffrey A Meyerhardt, Denise Heseltine, Hannia Campos, et al.
Cancer Journal (Sudbury, Mass.)|November 6, 2002
A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancerMatthew H Kulke, George D Demetri, Norman E Sharpless, et al.
The Lancet. Oncology|May 10, 2015
Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 studyAlexandria T Phan, Daniel M Halperin, Jennifer A Chan, et al.
Endocrine-Related Cancer|March 24, 2022
Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance)Matthew H Kulke, Fang-Shu Ou, Donna Niedzwiecki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2013
Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approachesKjell Oberg, Oriol Casanovas, Justo P Castaño, et al.
Carcinogenesis|June 13, 2009
Epidermal growth factor A61G gene polymorphism, gastroesophageal reflux disease and esophageal adenocarcinoma riskWinson Y Cheung, Rihong Zhai, Matthew H Kulke, et al.
Digestive Diseases and Sciences|January 18, 2006
A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinomaPeter C Enzinger, Matthew H Kulke, Jeffrey W Clark, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2006
Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancerJeffrey A Meyerhardt, Andrew X Zhu, Peter C Enzinger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumorsMatthew H Kulke, Jason L Hornick, Christine Frauenhoffer, et al.
Pageof 19

Showing results (81-90 of 182) with videos related to

Sort By:
Pageof 19
Cancer|June 5, 2013
A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumorJennifer A Chan, Lawrence Blaszkowsky, Keith Stuart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2005
Assessment of a dietary questionnaire in cancer patients receiving cytotoxic chemotherapyJeffrey A Meyerhardt, Denise Heseltine, Hannia Campos, et al.
Cancer Journal (Sudbury, Mass.)|November 6, 2002
A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancerMatthew H Kulke, George D Demetri, Norman E Sharpless, et al.
The Lancet. Oncology|May 10, 2015
Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 studyAlexandria T Phan, Daniel M Halperin, Jennifer A Chan, et al.
Endocrine-Related Cancer|March 24, 2022
Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance)Matthew H Kulke, Fang-Shu Ou, Donna Niedzwiecki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2013
Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approachesKjell Oberg, Oriol Casanovas, Justo P Castaño, et al.
Carcinogenesis|June 13, 2009
Epidermal growth factor A61G gene polymorphism, gastroesophageal reflux disease and esophageal adenocarcinoma riskWinson Y Cheung, Rihong Zhai, Matthew H Kulke, et al.
Digestive Diseases and Sciences|January 18, 2006
A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinomaPeter C Enzinger, Matthew H Kulke, Jeffrey W Clark, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2006
Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancerJeffrey A Meyerhardt, Andrew X Zhu, Peter C Enzinger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumorsMatthew H Kulke, Jason L Hornick, Christine Frauenhoffer, et al.
Pageof 19